Dossier · ENVA · Dormant
ENVA · Enova International, Inc. · Stock research
Last analysed ·
Current thesis
Credit-normalisation plus origination growth still working, but the repricing has stalled: $242.93 on 2026-08-21 is 8.5% under the $265.45 high with RSI 37.6 after a +54.2% three-month run. Two August filings cut funding cost (ABS priced 2026-08-13 at 5.88% senior; NC LOC facility to SOFR+5.00% on 2026-08-14) — yet nothing company-dated resolves before the ~2026-10-22 Q3 print.
Kill line
A weekly close below $228 returns price inside the mid-July pre-print zone and gives back the entire post-Q2 advance; a Q3 net charge-off ratio above 7.6%, a net revenue margin at or under the guided 55% floor, or an OCC/Fed denial of Grasshopper would compound the break.
Pick status
Open commitment catalyst in 9dscored if the kill line above fires How this is scored →Latest analysis and events for ENVA —
As of 22 August 2026, the latest FrontierPicks analysis for Enova International, Inc. (ENVA): Credit-normalisation plus origination growth still working, but the repricing has stalled: $242.93 on 2026-08-21 is 8.5% under the $265.45 high with RSI 37.6 after a +54.2% three-month run. Two August filings cut funding cost (ABS priced 2026-08-13 at 5.88% senior; NC LOC facility to SOFR+5.00% on 2026-08-14) — yet nothing company-dated resolves before the ~2026-10-22 Q3 print.
Kill line: A weekly close below $228 returns price inside the mid-July pre-print zone and gives back the entire post-Q2 advance; a Q3 net charge-off ratio above 7.6%, a net revenue margin at or under the guided 55% floor, or an OCC/Fed denial of Grasshopper would compound the break.
Next dated event on file: — catalyst in 9d.
Current Thesis
The Q2 binary resolved in July and the stock has since done a full round of the move: a new 52-week high at $265.45, then an 8.5% fade to a $242.93 reference close on 2026-08-21, with RSI(14) at 37.6 and a three-month price change of +54.2%. Nothing in the operating record has broken. What changed since the 2026-08-08 note is the funding stack, and it changed in the direction the bull case needs: on 2026-08-13 an Enova subsidiary priced $300.886M of NetCredit asset-backed notes (Class A 5.88%, B 7.68%, C 10.64%) against roughly $316.72M of unsecured consumer installment loans, and on 2026-08-14 the NC LOC 2024 facility was upsized from $200M to $300M with the borrowing rate cut from SOFR+5.50% to SOFR+5.00% and final maturity pushed to 2030-02-21. The narrative leg on offer is 20%+ origination growth financed at a falling cost of funds, with charge-offs holding near the 7.3% Q2 level. It is a maturing narrative: well known, still delivering, but the price is now working off an overbought condition rather than making new ground, and no company-dated catalyst falls before the ~2026-10-22 Q3 print.
Bullish and bearish views on Enova International, Inc.
The model's bull view on Enova International, Inc. (ENVA), in brief: Q2 2026 (2026-07-23): total revenue $929M, +22% YoY; net revenue $568M; net revenue margin 61% against 58% a year earlier and above the company's own 55–60% guide. The bear view: The company guided the margin back down itself: Q3 2026 is framed at a 55–60% net revenue margin against the 61% just printed. Both cases follow in full.
Bull Case
- Q2 2026 (2026-07-23): total revenue $929M, +22% YoY; net revenue $568M; net revenue margin 61% against 58% a year earlier and above the company's own 55–60% guide.
- Adjusted EPS $4.31 (+33% YoY), GAAP diluted EPS $4.00 (+40%), adjusted EBITDA $256M (+26%); guidance lifted to FY2026 revenue growth of 20–25% and adjusted EPS growth of 30–35%.
- Originations $2.3B, +27% YoY on the 2026-07-23 call — the eleventh straight quarter of at least 20% growth. Combined loans and finance receivables $5.5B, +28% YoY, with small business at 69% of receivables and revenue +35% YoY.
- Consolidated net charge-off ratio 7.3%, down from 8.1% a year earlier and 7.6% in Q1 2026; consumer NCO 12.8%, small business NCO 4.8%.
- Cost of funds 8.1% in Q2 versus 8.8% a year earlier — and the two August actions extend that line: SOFR+5.00% on the amended NC LOC 2024 facility (2026-08-14) versus SOFR+5.50% before, plus a term ABS printed 2026-08-13 with a 5.88% senior coupon.
- Capital return continued alongside the growth: $19M of stock repurchased in Q2 2026, liquidity of $929M.
- The pullback has reopened a gap to published targets. Post-print marks reported in late July run to $283 (Seaport, raised from $210) and $257 (TD Cowen), against earlier raises to $280 (Jefferies, 2026-07-08), $270 (BTIG, 2026-06-30) and $270 (Citizens, 2026-06-26). At $242.93 spot sits below every one of them.
Bear Case
- The company guided the margin back down itself: Q3 2026 is framed at a 55–60% net revenue margin against the 61% just printed. The beat is not carried forward.
- Management said on 2026-07-23 that some consumer metrics may move back toward more typical levels. Consumer is 31% of receivables but carries the 12.8% charge-off ratio, so blended credit moves with mix as much as with underwriting.
- The subordinate ABS tranches priced 2026-08-13 at 7.68% and 10.64%. Senior-tranche improvement does not tell you the whole cost curve, and consumer ABS spreads are the transmission channel if risk appetite turns.
- Grasshopper Bank ($369M, announced 2025-12-11, application filed 2026-01-16) is still open. It needs OCC and Federal Reserve approval plus Grasshopper stockholder approval, and American Banker reported a coalition of 20 state attorneys general urging federal regulators to reject bank purchases by Enova and OppFi. Consideration is part cash, part newly issued Enova shares, so the charter and the dilution land together.
- Insider supply has met the strength. A Form 4 filed 2026-07-16 shows Executive Chairman David Fisher exercising 28,500 options at $20.73 and selling into the open market on 14–15 July at weighted-average prices of $231.454 and $231.5061, leaving 306,444 shares held directly.
Setup & Price Structure
- Reference close $242.93 on 2026-08-21; 52-week high $265.45; the shares are 8.5% below that high with RSI(14) at 37.6 — a momentum name in a corrective phase, not a breakdown so far.
- That strike marks where the top of the run was priced only two and a half weeks before the current quote.
- The pre-print shelf is the reference structure below: shares changed hands between $225.64 and $235.4298 on 14–15 July, ahead of the 2026-07-23 report. A weekly close under $228 puts price back inside that zone and gives up the entire post-Q2 advance.
- Crowding observables, stated plainly: a +54.2% three-month move into a new high; a $257.79 grant strike at the top; open-market insider sales at ~$231.45 the week before the print; no earnings date inside 30 days to force a repricing; sell-side targets clustered $257–$283, i.e. above spot but no longer 30–40% above it as they were in late June.
Catalyst Calendar (next 30 days)
- ~2026-09-04 (BLS schedule): August US employment report. The labour market is the upstream driver of near-prime charge-offs; the 7.3% consolidated NCO is the assumption the current multiple pays for.
- 2026-09-16: FOMC decision and Summary of Economic Projections. Enova's warehouse lines are SOFR-linked (NC LOC 2024 now at SOFR+5.00%), so the path of the front end feeds the cost-of-funds line directly.
- ~2026-10-22 (est.): Q3 2026 earnings — outside the 30-day window. Nothing company-dated resolves before then.
Elapsed catalysts
- Open, 2H 2026 (application filed 2026-01-16): OCC / Federal Reserve decision on the $369M Grasshopper Bank acquisition. No public decision date. (passed 222d ago)
What Would Change Our Mind
The structure that matters is the July pre-print shelf, not the August high. Price giving that back would say the post-Q2 re-rating was a one-print event rather than the start of a multi-quarter revision cycle: a weekly close below $228 is the gradeable version of that break. On fundamentals, a Q3 consolidated net charge-off ratio above 7.6% would reverse the credit-normalisation trend that carried the last four quarters, and a Q3 net revenue margin at or below the guided 55% floor would end the beat cadence the multiple assumes. On the strategic leg, an OCC or Federal Reserve denial — or management dropping the close-this-year language on the Q3 call — removes both the cheaper-funding argument and the >25% accretion management guided to on 2026-07-23. The reverse case: a Grasshopper approval announcement, or a subsequent securitisation pricing inside the 5.88% senior coupon printed 2026-08-13, would extend the funding leg the two August filings started.
Correlation Notes
- Funding: SOFR-linked warehouse debt plus term ABS means the name trades with front-end rate expectations and with consumer ABS spreads, which can move independently of the policy rate. The 2026-08-13 print gives a live spread marker to compare the next deal against.
- Credit cohort: moves with high-APR consumer lenders (OppFi, Oportun, World Acceptance) on charge-off and regulatory headlines. The 20-state-AG letter reported by American Banker named Enova and OppFi together, so bank-charter headlines are a shared factor, not an idiosyncratic one.
- Mix: at 69% of receivables, small business ties the book to SMB credit conditions more than the consumer-lender label implies; the two segments printed 4.8% and 12.8% net charge-off ratios in Q2 2026.
- Macro: monthly payrolls and delinquency data are the visible drivers between prints, which is why a 30-day window with no company event leaves the tape hostage to 2026-09-04 and 2026-09-16.
Notes
- Q2 2026 reported 2026-07-23; next scheduled report ~2026-10-22 (est.). No company-dated catalyst falls inside the next 30 days.
- Grasshopper Bank ($369M, announced 2025-12-11) is part cash, part newly issued Enova shares — closing brings a bank charter and dilution at the same time.
- High-APR lending carries a standing federal and state regulatory tail; American Banker reported 20 state attorneys general urging regulators to reject the bank deal.
- Adjusted EPS ($4.31 in Q2 2026) sits above GAAP diluted EPS ($4.00) — check which measure a headline quotes before comparing to consensus.
- Consumer is ~31% of receivables at a 12.8% net charge-off ratio versus 4.8% for small business; blended NCO moves with mix as well as with credit quality.
- Warehouse funding is SOFR-linked (NC LOC 2024 at SOFR+5.00% after the 2026-08-14 amendment) and term funding is ABS-dependent, so spreads matter alongside the policy rate.
Related · shared themes
DAVE
Dave Inc.
Beat-and-raise fully modelled by 13 firms and sold on the day; the recovery has now stalled under $358–360 for three weeks, with the 2026-08-24 close at $354.79 and RSI(14) at 31.8. No rating action since 2026-08-17 and nothing operating until Q3 around 2026-11-04 — the ~2026-08-26 short-interest print is the only dated item left in the month.
SEZL
Sezzle Inc.
Growth leg was retired by management's own 2026-08-06 H2 guide and the −33.89% gap; only a re-rating argument is live at 19.68x forward on the 2026-08-24 close of $117.93. That close lost the $118.02/$118.00 shelf with RSI(14) at 21.5, $129.87 untouched since 2026-08-17, and no Sezzle-generated datapoint until ~2026-11-05 — the nearest dated event is Affirm's 2026-08-27 print.
KYMR
Kymera Therapeutics, Inc.
Oral STAT6 degrader (KT-621) re-rated on early BROADEN2 enrollment (6/25) and the $10.9B AbbVie–Apogee read-through, but the analyst upgrade cycle topped with RBC's 7/13 downgrade to neutral and the binary topline is 2H-2026 — a maturing, stretched theme structurally supported on a pullback to the $100 shelf rather than into the catalyst gap.
SYRE
Spyre Therapeutics, Inc.
Two of three lead binaries (SPY001, SPY002 anti-TL1A) printed potential best-in-class; the stock absorbed a ~$399.7M director-fund block sale and sits back near its ~$102 ATH (~$95). Next legs — SPY003 IL-23 Part A (guided mid-2026, overdue) and SPY072 RA topline (accelerated to Q3) — are the near-term binaries. Platform de-risked, but distribution flags plus ~1:1 R/R to $100–135 targets argue probe-only into an all-time high.
See also · stocks to watch